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INTRODUCTION: Recent practice guidelines suggest applying non-invasive
ventilation (NIV) to prevent postextubation respiratory failure in patients at high
risk of extubation failure in intensive care unit (ICU). However, such prophylactic
NIV has been only a conditional recommendation given the low certainty of
evidence. Likewise, high-flow nasal cannula (HFNC) oxygen therapy has been
shown to reduce reintubation rates as compared with standard oxygen and to be as
efficient as NIV in patients at high risk. Whereas HFNC may be considered as an
optimal therapy during the postextubation period, HFNC associated with NIV could
be an additional means of preventing postextubation respiratory failure. We are
hypothesising that treatment associating NIV with HFNC between NIV sessions
may be more effective than HFNC alone and may reduce the reintubation rate in
patients at high risk.
METHODS AND ANALYSIS: This study is an investigator-initiated, multicentre
randomised controlled trial comparing HFNC alone or with NIV sessions during the
postextubation period in patients at high risk of extubation failure in the ICU. Six
hundred patients will be randomised with a 1:1 ratio in two groups according to the
strategy of oxygenation after extubation. The primary outcome is the reintubation
rate within the 7 days following planned extubation. Secondary outcomes include
the number of patients who meet the criteria for moderate/severe respiratory
failure, ICU length of stay and mortality up to day 90.
ETHICS AND DISSEMINATION: The study has been approved by the ethics
committee and patients will be included after informed consent. The results will be
submitted for publication in peer-reviewed journals.
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